Omics-based biomarkers: current status and potential use in the clinic
In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is describe...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Permanyer
2017-05-01
|
Series: | Boletín Médico del Hospital Infantil de México |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665114617300680 |
id |
doaj-038215ac985346c2b69f6145e76dab71 |
---|---|
record_format |
Article |
spelling |
doaj-038215ac985346c2b69f6145e76dab712021-04-02T13:59:54ZengPermanyerBoletín Médico del Hospital Infantil de México1665-11462017-05-0174321922610.1016/j.bmhimx.2017.03.003Omics-based biomarkers: current status and potential use in the clinicHéctor Quezada0Ana Laura Guzmán-Ortiz1Hugo Díaz-Sánchez2Ricardo Valle-Rios3Jesús Aguirre-Hernández4Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Genómica, Genética y Bioinformática, Hospital Infantil de México Federico Gómez, Mexico City, MexicoIn recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes.http://www.sciencedirect.com/science/article/pii/S1665114617300680BiomarkerGenomicsProteomicsMetabolomics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Héctor Quezada Ana Laura Guzmán-Ortiz Hugo Díaz-Sánchez Ricardo Valle-Rios Jesús Aguirre-Hernández |
spellingShingle |
Héctor Quezada Ana Laura Guzmán-Ortiz Hugo Díaz-Sánchez Ricardo Valle-Rios Jesús Aguirre-Hernández Omics-based biomarkers: current status and potential use in the clinic Boletín Médico del Hospital Infantil de México Biomarker Genomics Proteomics Metabolomics |
author_facet |
Héctor Quezada Ana Laura Guzmán-Ortiz Hugo Díaz-Sánchez Ricardo Valle-Rios Jesús Aguirre-Hernández |
author_sort |
Héctor Quezada |
title |
Omics-based biomarkers: current status and potential use in the clinic |
title_short |
Omics-based biomarkers: current status and potential use in the clinic |
title_full |
Omics-based biomarkers: current status and potential use in the clinic |
title_fullStr |
Omics-based biomarkers: current status and potential use in the clinic |
title_full_unstemmed |
Omics-based biomarkers: current status and potential use in the clinic |
title_sort |
omics-based biomarkers: current status and potential use in the clinic |
publisher |
Permanyer |
series |
Boletín Médico del Hospital Infantil de México |
issn |
1665-1146 |
publishDate |
2017-05-01 |
description |
In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes. |
topic |
Biomarker Genomics Proteomics Metabolomics |
url |
http://www.sciencedirect.com/science/article/pii/S1665114617300680 |
work_keys_str_mv |
AT hectorquezada omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic AT analauraguzmanortiz omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic AT hugodiazsanchez omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic AT ricardovallerios omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic AT jesusaguirrehernandez omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic |
_version_ |
1721563342163673088 |